Back to results
US 2016/0273048 A1Published application
Methods for the surveillance, diagnosis and screening of bladder cancer
AssigneeOncodiag
InventorJean-Pierre Roperch
Life of this patent
Estimating the term…
Abstract
The invention relates to a method of diagnosing or predicting a bladder cancer, or a risk of a developing a bladder cancer in a subject, which method comprises the detection of specific mutations in the FGFR3 gene in a first biological sample; and the measure of the degree of methylation of target genes in a biological sample obtained from said subject in a second biological sample,
Claims20
A method for the surveillance, diagnosis and screening of a bladder cancer, or a risk of a developing a bladder cancer in a subject, wherein said method comprises:
- a) a step of detecting a mutation in the FGFR3 gene in a first biological sample;
- and
- b) a step of measuring the degree of methylation of at least two genes selected from the group consisting of SEPTIN 9, SLIT 2, TWIST 1, HS3ST2 and fragments or variants thereof in a second biological sample obtained from said subject,
- wherein
- said first and second biological samples are the same biological sample;
- and
- said step a) is performed by:
- detecting a mutation selected from the group consisting of 742C→T, 746C→G, 1114G→T, and 1124A→G by reference to the nucleotide numbers of SEQ ID No 1;
- or
- detecting a mutation in the group consisting of mutations Arg248Cys, Ser249Cys, Gly372Cys, and Tyr375Cys, by reference to the aminoacid numbers of SEQ ID NO. 2.
7 more elements
A kit comprising:
- (a) at least one oligonucleotide selected from the group consisting of SEQ ID NOS. 8 to 13;
- and
- (b) at least one oligonucleotide selected from the group consisting of SEQ ID NOS. 16 to 30.
Dependencies are inferred from the claim text.